All In Biotech

Drug Trial Radar · NCT06342921

ADC189 Tablets on Influenza A Virus Infection/Influenza B Virus Infection

A Multicenter, Randomized, Double-blind, Placebo-controlled Phase II/III Study of the Safety and Efficacy of ADC189 Tablets in the Treatment of Influenza A Virus Infection/Influenza B Virus Infection in Adolescents and Adults

Last checked: Nov 19, 2026Latest source record: Jan 21, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

CompletedPivotal-lookingPhase 3. Randomized with 749 participants. This is a heuristic, not a regulatory label.

Status

Completed

Enrollment

749

Actual

Start

Dec 7, 2022

Primary completion

Oct 8, 2023

Study completion Jan 22, 2024

Sponsor

Sponsor type
Industry
First posted
Apr 2, 2024

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2 / Phase 3
Allocation
Randomized
Model
Parallel
Masking
Quadruple (participant, care provider, investigator, outcomes assessor)
Primary purpose
Treatment
FDA-regulated drug
No
Who can join
All sexes, from 12 years, up to 65 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The goal of this Phase II/III study is to investigate the safty and efficacy of ADC189 tablets in adolescents and adults with influenza A virus infection/influenza B virus infection. The main aim to answer: * Phase II study is to evaluate the efficacy of ADC189 tablets in the treatment of adult influenza subjects and determine the optimal therapeutic dose by analyzing the time of virus titer turning to negative. All the results will be used to design the Phase III study. * Phase III study is to evaluate the efficacy of ADC189 tablets by analyzing the duration of remission of all influenza symptoms in adolescents and adults subjects with influenza. Participants will be taken ADC189 teblets/Placebo once, and be observed by 22 days. Phase II study has 3 groups: 15 mg ADC189; 45 mg ADC189; and Placebo; Phase III study has 2 groups: 45 mg ADC189; and Placebo.

Conditions

  • Safety Issues
  • Effect of Drug

Interventions

  • 15 mg ADC189Drug

    Use only once during the whole study.

  • 45 mg ADC189Drug

    Use only once during the whole study.

  • PlaceboDrug

    Use only once during the whole study.

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. the severity of influenzaTime frame: 22 days
  2. the safety of study drugTime frame: 22 days

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • Rui Jin Hospital

    Shanghai, Shanghai Municipality, China

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.